このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Nurix Therapeutics 過去の業績
過去 基準チェック /06
Nurix Therapeuticsの収益は年間平均-36.7%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間15.5% 44.3%割合で 増加しています。
主要情報
-36.7%
収益成長率
19.8%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | 44.3% |
| 株主資本利益率 | -85.8% |
| ネット・マージン | -178.9% |
| 前回の決算情報 | 29 Feb 2024 |
最近の業績更新
Recent updates
Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case
Jun 19What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You
May 29
Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
Apr 15Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues
Apr 14Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet
Feb 20Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now
Jan 16Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Dec 29Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues
Oct 14Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Oct 13Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Sep 30Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts
Apr 18We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Apr 15We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
Nov 28Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M
Oct 06Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M
Jul 07FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.
Jun 30We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Jun 21We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth
Mar 07Nurix: Advancing Targeted Protein Modulation Therapies
Nov 21Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth
Nov 21We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn
Jul 24Nurix Therapeutics appoints new operations chief
Jun 21Nurix Therapeutics adds Clay Siegall to its board of directors
Jun 01収支内訳
収支内訳
Nurix Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 29 Feb 24 | 81 | -145 | 45 | 0 |
| 30 Nov 23 | 77 | -144 | 43 | 0 |
| 31 Aug 23 | 69 | -149 | 41 | 0 |
| 31 May 23 | 61 | -157 | 41 | 0 |
| 28 Feb 23 | 42 | -179 | 39 | 0 |
| 30 Nov 22 | 39 | -180 | 38 | 0 |
| 31 Aug 22 | 39 | -171 | 37 | 0 |
| 31 May 22 | 39 | -154 | 36 | 0 |
| 28 Feb 22 | 34 | -135 | 34 | 0 |
| 30 Nov 21 | 30 | -117 | 31 | 0 |
| 31 Aug 21 | 29 | -99 | 29 | 0 |
| 31 May 21 | 23 | -89 | 25 | 0 |
| 28 Feb 21 | 20 | -63 | 20 | 0 |
| 30 Nov 20 | 18 | -43 | 16 | 0 |
| 31 Aug 20 | 13 | -37 | 13 | 0 |
| 31 May 20 | 19 | -21 | 11 | 0 |
| 29 Feb 20 | 25 | -24 | 9 | 0 |
| 30 Nov 19 | 31 | -22 | 8 | 0 |
| 30 Nov 18 | 37 | -9 | 7 | 0 |
質の高い収益: NRIXは現在利益が出ていません。
利益率の向上: NRIXは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: NRIXは利益が出ておらず、過去 5 年間で損失は年間36.7%の割合で増加しています。
成長の加速: NRIXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: NRIXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。
株主資本利益率
高いROE: NRIXは現在利益が出ていないため、自己資本利益率 ( -85.77% ) はマイナスです。